Trending Topic

Breast Cancer
29 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Endocrine therapy (ET) has changed the natural history of hormone receptor-positive (HR+) breast cancer (BC) and is the cornerstone of the treatment of HR+ BC. There are several ETs approved for the treatment of BC, including selective oestrogen receptor modulators (SERMs; tamoxifen), aromatase inhibitors (AIs; anastrazole, letrozole and exemestane) and selective oestrogen receptor degraders (SERDs; fulvestrant […]

Carmelo Rizzari: Main Take Away Messages from the SIOP Europe 2022 Annual Meeting

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Apr 25th 2022

Professor Carmelo Rizzari, President of the European Society of Paediatric Oncology (SIOP Europe), explains who the Annual Meeting is aimed at, who is involved and what were the main take-away messages from this year’s conference.

Questions

  1. Who were the participants of the SIOPE Annual Meeting? (01:00-02:29)
  2. What is the main message you wish to share with the community following this event? (02:29-05:07)

Speaker Disclosure: Speaker Disclosure: Carmelo Rizzari has been a consultant for Jazz Pharmaceutcials, Amgen, Servier and Clinigen. He has received grant and research support from: SERB, Jazz Pharmaceutcials, Amgen, Servier and Clinigen. He has received honoraria/honorarium from: Jazz Pharmaceutcials, Amgen, Servier, Clinigen. He has been a speaker’s bureau participant with: Jazz Pharmaceutcials, Amgen, Servier and Clinigen.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.

Filmed in coverage of SIOP Europe 2022

 

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup